GRAPEFRUIT JUICE AND DRUGS - HOW SIGNIFICANT IS THE INTERACTION

被引:162
作者
BAILEY, DG
ARNOLD, JMO
SPENCE, JD
机构
[1] VICTORIA HOSP,RES INST,LONDON,ON,CANADA
[2] UNIV WESTERN ONTARIO,DEPT PHARMACOL & TOXICOL,LONDON,ON,CANADA
关键词
D O I
10.2165/00003088-199426020-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The serendipitous finding that grapefruit juice interacts with felodipine was subsequently found to be valid for some other dihydropyridines, but this interaction is probably not limited to this class of drugs. The clinical relevance of the grapefruit juice interaction with each particular drug will depend on the magnitude of change in the pharmacokinetic profile of the drug, the drug concentration-response relationships and the patient. Since current information indicates that the interaction is variable and unpredictable, it appears reasonable to caution patients not to ingest grapefruit juice at the same time as taking felodipine and other dihydropyridines. Identification of the active ingredient in grapefruit juice may allow the prediction of other foods that may also interact with dihydropyridines and some other drugs. Furthermore, it may lead to exploitation of the inhibitory effects of the active ingredient(s), and its inclusion into drug formulations to increase the clinical efficacy of orally administered drugs. It seems that this discovery has provided fundamental new knowledge both to improve pharmacotherapy and to stimulate further research. © 1994, Adis International Limited. All rights reserved.
引用
收藏
页码:91 / 98
页数:8
相关论文
共 38 条
[1]   PHARMACOKINETICS OF CALCIUM-ANTAGONISTS UNDER DEVELOPMENT [J].
ABERNETHY, DR ;
SCHWARTZ, JB .
CLINICAL PHARMACOKINETICS, 1988, 15 (01) :1-14
[2]  
BAILEY DG, 1989, CLIN INVEST MED, V12, P357
[3]   GRAPEFRUIT JUICE FELODIPINE INTERACTION - MECHANISM, PREDICTABILITY, AND EFFECT OF NARINGIN [J].
BAILEY, DG ;
ARNOLD, JMO ;
MUNOZ, C ;
SPENCE, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (06) :637-642
[4]   EFFECT OF GRAPEFRUIT JUICE AND NARINGIN ON NISOLDIPINE PHARMACOKINETICS [J].
BAILEY, DG ;
ARNOLD, JMO ;
STRONG, HA ;
MUNOZ, C ;
SPENCE, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (06) :589-594
[5]   INTERACTION OF CITRUS JUICES WITH FELODIPINE AND NIFEDIPINE [J].
BAILEY, DG ;
SPENCE, JD ;
MUNOZ, C ;
ARNOLD, JMO .
LANCET, 1991, 337 (8736) :268-269
[6]  
BAILEY DG, 1992, CLIN PHARMACOL THER, V51, P156
[7]  
BAILEY DG, 1994, IN PRESS CLIN PHARM, V55
[8]   A POPULATION STUDY OF THE PHARMACOKINETICS OF FELODIPINE [J].
BLYCHERT, E ;
EDGAR, B ;
ELMFELDT, D ;
HEDNER, T .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (01) :15-24
[9]   PLASMA-CONCENTRATION EFFECT RELATIONSHIPS OF INTRAVENOUS AND EXTENDED-RELEASE ORAL FELODIPINE IN HYPERTENSIVE PATIENTS [J].
BLYCHERT, E ;
HEDNER, T ;
DAHLOF, C ;
ELMFELDT, D .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 15 (03) :428-435
[10]   OPTIMAL FELODIPINE DOSE WHEN COMBINED WITH METOPROLOL IN ARTERIAL-HYPERTENSION - A SWEDISH MULTICENTER STUDY WITHIN PRIMARY HEALTH-CARE [J].
BRUN, J ;
FROBERG, L ;
KRONMANN, P ;
OLSSON, LB ;
SKOOG, P ;
TYGESEN, G ;
BENGTSSON, C ;
SCHERSTEN, B ;
TIBBLIN, G .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 15 :S60-S64